Objectives To inform strategic decisions on respiratory syncytial virus (RSV) vaccine
development and identify critical endpoints likely to drive the vaccine's medical and
economic impact. Design A decision-analysis model populated using healthcare utilization
data and costs from the literature; vaccine efficacy and duration based on assumptions.
Setting Vaccination in the physician office setting in the USA. Participants A hypothetical
cohort of newborn infants. Intervention Vaccination of children at low and high risk of …